Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Phospholipase A2 receptor related membranous nephropathy (PLA2R-MN) accounts for approximately 50-80% of primary membranous nephropathy. The main pathogenic factor of PLA2R-MN is IgG4 which serves as a weak activator of complement pathway. IgG4 subclass is a common subclass in chronic allergic reactions which are typically initiated by specific IgE. There were no study screens IgE deposition in PLA2R-MN. This study established a method for detecting IgE in PLA2R-MN. We analyzed the relationship between IgE deposition and disease activity of PLA2R-MN.
We collected patients who underwent renal biopsy from February 2022 to May 2025. Method was set up with positive control: PLA2R-MN with serum PLA2R antibody, lupus membranous nephropathy; negative control: non PLA2R-MN, non-MN with immune complex deposit and oligoimmune complex nephropathy. The clinical, laboratory, and pathological data of 111 PLA2R-MN patients during renal biopsy were collected including gender, age, 24-hour urinary protein (24hUP), plasma albumin (Alb), serum creatinine (Scr), and anti-PLA2R antibody titter. According to the presence of IgE deposition in the glomerulus, the samples were divided into two groups-IgE positive group (39,35%) and IgE negative group (62,65%).
The renal outcomes comparison between two groups were as follows. The IgG deposit was 1.9 ± 0.6 vs. 2.2 ± 0.7, P = 0.018; IgA deposit was 0.1 ± 0.3 vs. 0.2 ± 0.5, P = 0.352; C3 deposit was 0.3 ± 0.3, vs. 0.7 ± 0.6, P ＜ 0.001; C1q deposit was 0.04 ± 0.17 vs. 0.30 ± 0.41, P ＜ 0.001; Electron microscopy stage was 2.1 ± 1.1 vs. 2.1 ± 1.1, P = 0.937; PLA2R antigen was 0.7 ± 0.3 vs. 0.9 ± 0.41, P = 0.002; Median serum PLA2R antibody was 0 (0,0) RU/mL vs. 3.5 (0,3.5) RU/mL, P = 0.005; 24hUP was 3.7 ± 4.4 vs. 4.1 ± 2.8, P = 0.076; Median sCr was 61 (50,72) mmol/L vs. 68 (59,86) mmol/L, P = 0.007; Serum Alb was 32.3±5.8g/L vs. 30.4±6.7g/L, P = 0.073; estimated glomerular filtration rate was 104 (93,125) mL·min-1(1.73m2)-1 vs. 101 (78,112) mL·min-1(1.73m2)-1, P = 0.009.
We established a detection method for IgE in PLA2R-MN. In PLA2R-MN, patients with IgE depositions had higher complement and IgG depositions in renal, expressed more PLA2R antigen, showed higher levels of serum PLA2R antibodies and with poorer renal function.
